Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CNTB
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) P/E ratio
Connect Biopharma Holdings Limited Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)